



## OvaScience to Present at the JMP Securities Healthcare Conference

June 18, 2014

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 18, 2014-- OvaScience<sup>SM</sup>, (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today that Arthur Tzianabos, Ph.D., Chief Scientific Officer of OvaScience, will present at the JMP Securities Healthcare Conference on Wednesday, June 25, 2014 at 11:30 am ET in The Westin New York Grand Central.

A live audio webcast of the presentation can be accessed by visiting the Investor section of the Company's website at [www.ovascience.com](http://www.ovascience.com). A replay of the webcast will be archived on the OvaScience website for two weeks following the presentation.

### About OvaScience

OvaScience (NASDAQ: OVAS) is a global life sciences company focused on the discovery, development and commercialization of new fertility treatments. The Company's patented technology is based on the discovery of egg precursor cells (EggPC<sup>SM</sup>), which are found in the ovaries. By applying proprietary technology to identify and isolate EggPCs, OvaScience is developing potential next generation *in vitro* fertilization (IVF) treatments. The Company currently has three fertility treatments in development: AUGMENT<sup>SM</sup>, which aims to improve egg quality and increase the success of IVF; OvaPrime<sup>SM</sup>, designed to boost a woman's egg reserve using her own EggPCs; and OvaTure<sup>SM</sup>, which seeks to create mature fertilizable eggs from a woman's own EggPCs without the need for hormone injections. OvaScience's team of scientists, physicians and advisers includes recognized leaders in the field of reproductive medicine. For more information, please visit [www.ovascience.com](http://www.ovascience.com) and connect with us on [Twitter](#) and [Facebook](#).

### Forward-Looking Statements

*This press release includes forward-looking statements about the Company's plans for its three fertility treatments in development. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: our expectation that AUGMENT and OvaPrime meet the requirements of a class of products exempt from premarket review and approval under applicable regulations in those countries where we plan to introduce AUGMENT and OvaPrime; the science underlying our product candidates (including AUGMENT, OvaPrime and OvaTure), which is unproven; our ability to obtain regulatory approval for our product candidates; our ability to develop our product candidates, including AUGMENT, OvaPrime and OvaTure, on the timelines we expect, if at all; our ability to commercialize our product candidates, including AUGMENT and OvaPrime, on the timelines we expect, if at all; as well as those risks more fully discussed in the "Risk Factors" section of our most recently filed Quarterly Report on Form 10-Q or Annual Report on Form 10-K. The forward-looking statements contained in this press release reflect our current views with respect to future events. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our view as of any date subsequent to the date hereof.*

###

Source: OvaScience, Inc.

OvaScience, Inc.  
Theresa McNeely, 617-299-7356  
EVP, Strategic Corporate Communications  
[tmcneely@ovascience.com](mailto:tmcneely@ovascience.com)